 | | Vol. 5.33 – 21 September, 2020 |
| |
|
|
| Researchers found that GSK-3β phosphorylated FBXL21 and TCAP to activate FBXL21-mediated, phosphodegron-dependent TCAP degradation. GSK-3β inhibition or knockdown diminished FBXL21-Cul1 complex formation and delayed FBXL21-mediated TCAP degradation.
[Cell Reports] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Investigators report a cardiomyocyte-specific survival upon proteasome inhibition in a heterogeneous culture consisting of cardiomyocytes and other three major cardiac cell types.
[Cell Death & Disease] |
|
|
|
| Scientists demonstrated that direct delivery of large amounts of transgene encoding guide RNA and repair template DNA via intra-ventricular injection of adeno-associated virus promoted precise targeted genome replacement in adult murine cardiomyocytes expressing Cas9.
[Scientific Reports] |
| |
|
|
| Researchers showed that SWELL1 functionally encoded a swell-activated anion channel that regulated PI3K-AKT, ERK1/2, mTOR signaling, muscle differentiation, myoblast fusion, cellular oxygen consumption, and glycolysis in skeletal muscle cells.
[eLife] |
|
|
|
| Using 850K DNA methylation arrays, the authors compared the methylomes of young and aged human skeletal muscle and that of young/aged heterogenous muscle-derived human primary cells over several time points of differentiation.
[Scientific Reports] |
|
|
|
| Catalpol administration had no effect on dystrophin expression, but exerted anti-inflammatory effects. Catalpol administration dose-dependently decreased tibialis anterior muscle fibrosis, and inhibited the expression of TGF-β1, TAK1 and α-SMA. In primary myoblasts from mdx mice, knockdown of TAK1 abolished the inhibitory effects of catalpol on the expression levels of TGF-β1 and α-SMA.
[Acta pharmacologica Sinica] |
| |
|
|
| Researchers investigated whether choline modulates vascular smooth muscle cell phenotypic changes and explored the underlying mechanisms.
[Arteriosclerosis Thrombosis and Vascular Biology] |
|
|
|
| Scientists discovered that BCAT1 bound IRE1 on the endoplasmic reticulum to activate expression of its downstream pathway XBP-1-RIDD axis to activate autophagy. They identified an RNA-binding protein, zinc finger protein 423, which promoted autophagy by binding adenylate/uridylate-rich elements in the BCAT1 mRNA 3′-untranslated region.
[Cell Death & Disease] |
|
|
|
|
| Researchers provide an overview of the available knowledge of body wasting and physical frailty in patients with cardiovascular illness, particularly focusing on patients with heart failure in whom most of the available data has been gathered.
[European Journal of Heart Failure] |
|
|
|
| The authors discuss the cellular and functional alterations upon ischemia/reperfusion (I/R) especially in aging hearts. They propose that mitochondria are the primary source of reactive oxygen species that contribute to I/R injury in aged hearts. Then, they highlight the cardiomyocyte protection of the age-related proteins Sirtuin1 and Sirtuin1 in response to I/R injury, and discuss their modulation of cardiac metabolism and the inflammatory reaction that is involved in ROS formation.
[Antioxidants] |
|
|
|
|
| Immunity Pharma announced interim results from its Phase I/IIa clinical study with IPL344, an Akt activating disease-modifying drug for the treatment of ALS. In this early stage clinical trial, disease progression rate during IPL344 treatment was about 50% slower than expected without treatment, in both functional and respiratory endpoints. The drug also demonstrated a very favorable safety and tolerability profile.
[Immunity Pharma Inc.] |
|
|
|
| Curi Bio announced the Mantarray™ platform for human-relevant 3D engineered muscle tissue (EMT) analysis. Curi’s Mantarray platform enables the discovery, safety, and efficacy testing of new therapeutics by providing parallel analysis of 3D EMTs with adult human-like functional profiles.
[Curi Bio] |
|
|
|
|
| November 11 – November 13
Virtual |
|
|
|
|
|
| | Swiss Federal Institute of Technology Zurich – Zürich, Switzerland |
|
|
|
| | Duke University – Durham, North Carolina, United States |
|
|
|
| | University of California, Davis – Davis, California, United States |
|
|
|
| | University of North Carolina at Chapel Hill – Chapel Hill, North Carolina, United States |
|
|
|
| | UPMC Children’s Hospital of Pittsburgh – Pittsburgh, Pennsylvania, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
